- GCVRZ is up 135% to $1.20 in early premarket action after the FDA approved Lemtrada late on Friday. The deadline for a $1 payment with FDA approval has passed, so the next milestone would be for $2 if the drug exceeds $400M in worldwide sales over a four-quarter period.
- The question: Is GCVRZ a better buy at $1.20 with approval in hand than at $0.50 without yet having approval?
- GCVRZ forum
- Previously: Genzyme's Lemtrada approved by the FDA
- SNY -0.2% premarket